3rd Annual IO Next Summit
- Beyond PD-1: Insights From Translational Oncologists On Novel IO Targets 2019
- Adaptimmune (ADAP)
- Aduro Biotech (ADRO)
- Alkermes (ALKS)
- Atara Biotherapeutics (ATRA)
- Five Prime Therapeutics (FPRX)
- Gritstone Oncology (GRTS)
- Iovance (IOVA)
- Macrogenics (MGNX)
- Mirati Therapeutics (MRTX)
- Nektar (NKTR)
- Pieris (PIRS)
- Unum Therapeutics (UMRX)
Click here for important disclosures.